1. Home
  2. ARDC vs PRLD Comparison

ARDC vs PRLD Comparison

Compare ARDC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ARDC

Ares Dynamic Credit Allocation Fund Inc.

HOLD

Current Price

$12.77

Market Cap

306.0M

Sector

Finance

ML Signal

HOLD

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$4.91

Market Cap

346.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARDC
PRLD
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
346.5M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
ARDC
PRLD
Price
$12.77
$4.91
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.67
AVG Volume (30 Days)
97.7K
523.6K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.21
EPS
N/A
N/A
Revenue
N/A
$12,140,000.00
Revenue This Year
N/A
$320.10
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
73.43
52 Week Low
$11.60
$0.75
52 Week High
$15.03
$5.69

Technical Indicators

Market Signals
Indicator
ARDC
PRLD
Relative Strength Index (RSI) 60.46 59.52
Support Level $12.43 $3.92
Resistance Level $12.85 $5.43
Average True Range (ATR) 0.11 0.44
MACD 0.02 0.10
Stochastic Oscillator 88.24 54.65

Price Performance

Historical Comparison
ARDC
PRLD

About ARDC Ares Dynamic Credit Allocation Fund Inc.

Ares Dynamic Credit Allocation Fund Inc is a closed-end, diversified, management investment company. The Fund's investment objective is to seek an attractive risk adjusted level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of (i) senior secured loans, (ii) corporate bonds, (iii) other fixed-income instruments, and (iv) securities issued by entities commonly referred to as collateralized loan obligations and other asset-backed securities.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Share on Social Networks: